Gemelli Biotech

Gemelli Biotech Corp. focuses on improving health by providing precise diagnostics for GI diseases. Founded in 2018, Gemelli's mission is to leverage leading biological discoveries related to the microbiome to deliver non-invasive precision diagnostics, enabling clinicians to definitively detect scientifically validated biomarkers and optimize the treatment of GI diseases, including SIBO, IMO, excess hydrogen sulfide, and post-infection irritable bowel syndrome. Gemelli Biotech's product portfolio includes the ibs-smart® blood test for diagnosing irritable bowel syndrome and the trio-smart® breath test, which provides a more comprehensive assessment of gut health.